To The Moon

$ALB.HK 20251230 55.00 PUT$ Closed the option because it's already 80% profit and no point keeping, eating up margin since it's a long term option

$TINGYI(00322)$  Trimmed the position at minor profits, aimed at long term dividend, little capital gains lower holding cost.

$AMD 20250822 165.0 PUT$ long put entry . Want to build a bear put ladder . This is a limited risk trade 

$Direxion Daily Small Cap Bear 3X Shares(TZA)$ Continued accumulation of tza using tiger voucher. $10 usd voucher for $10 usd stock. Effectively free excluding commissions 

$DBS(D05.SI)$ I realized the fees for SG stock under tiger.  I am shifting myself to a lower cost platform as SG stocks are my foundation for my dividend investing which is for my retirement.

$NVIDIA(NVDA)$ Piper Sandler Maintains NVIDIA(NVDA.US) With Buy Rating, Raises Target Price to $225 派杰投资维持英伟达(NVDA.US)买入评级，上调目标价至225美元

1/ $NEBIUS(NBIS)$ is my highest conviction stock for the next 5 years.Revenue is growing triple digits, and they are looking to quadruple the capacity by the end of next year.It's just starting off.Here is why it can make 3x in the next 2 years: 🧵2/ What does NBIS do?It's a full-stack AI infrastructure provider.What the hell does this mean?They build and operate their own data centers with their custom hardware.On top of this capacity, they have built a cloud business specifically for AI/ML workloads.Image3/ It has data centers in Europe and the US.Currently, the majority of the capacity comes from data centers in France and Finland.Yet, they are rapidly expanding in the US and have contracted another data center in the UK.So, what sets their data

$INNOVENT BIO(01801)$ 摩根大通最新研報力挺信達生物（01801），將目標價上調至109港元，予“增持”評級，列為行業首選！研報指出，對外授權成為內地生物醫藥核心驅動力，信達憑藉強大產品管線，覆蓋腫瘤、心血管、自身免疫及眼科等領域，多元化資產組合蓄勢待發，未來數年有望持續達成授權交易。摩根大通上調潛在授權收入佔比預測至5%-7%，並預期毛利率因銷售結構優化而擴張。信達研發能力獲市場高度認可，早期資產估值激增43%。憑藉領先的創新能力和多元化戰略，信達生物投資價值凸顯！

$Apple(AAPL)$ I recently added to my Apple position, driven by the company’s expanding push into AI. Apple’s new “Answers” team is developing a lightweight ChatGPT rival to enhance user access to world knowledge, signaling a more independent AI direction. While the iPhone 17 Pro’s early sighting hints at continued hardware innovation, Apple’s loss of AI talent to Meta and recent executive reshuffles highlight transitional challenges. I see these moves as part of a broader strategy shift that could unlock new growth streams, making the current market levels an attractive long-term entry point.

$MNDY 20250815 180.0 PUT$ MNDY: collect $490 (2.7%) premium on this at the money sold out with strike at $180.  Contract expires on this Friday 15th Aug.  MNDY had a sharp 30% fall after earnings. Spooked by poorer Q3 forecast guidance.  This is despite that MNDY beats its Q2 earnings and revenue so expects the market to focus heavily on the future that is slowing down.  Still, I think management might be sandbagging due to uncertainties and gave a more conservative guidance instead. The weaker forecast is only a tad lower than analyst expectations but the sell off was pretty severe.  Trying to bottom fish, but the options is now already in the money since the trade initiated.  With premium c

$TLT 20250815 86.0 PUT$ 我近來開始部署賣put長債$20+年以上美國國債ETF-iShares(TLT)$ 既put。不斷賣put87之下。我認為就算下個月不減息，在87之下接貨，利率接近4.5%，即使接貨仍可以作長線投資[贱笑]  。手上近既8月11,13同15號都有[胜利]   $TLT 20250813 86.0 PUT$   $TLT 20250815 86.0 PUT$  $TLT 20250811 87.0 PUT$  

$KUAISHOU-W(01024)$ 快手今日盤中重挫超8%，創四個月最大跌幅，報價跌8.56%。彭博社援引光大證券分析稱，跌勢因快手聯手美團上線外賣入口，市場憂慮競爭加劇損及盈利。快手“團購”新增外賣入口，依託美團小程序完成配送，屬第三方合作模式，未自建配送網。美團股價同步微跌0.67%，反映市場謹慎情緒。我認為市場對協同效應過分悲觀，快手與美團合作有望提升用戶粘性，跌幅過大或存投機買入機會，博短期反彈！

$KINGDEE INT'L(00268)$ 金蝶國際（00268.HK）上半年收入增11%至32億元，雲訂閱服務收入飆升22%至17億元，毛利率升至96.2%，展現強勁增長動能。訂閱服務ARR增18%至37.3億元，雲訂閱合約負債增25%至34億元，凸顯市場信心。AI業務亮眼，上半年合約額超1.5億元，後續雲業務收入、盈利前景及AI長期規劃備受期待。儘管中小企非訂閱收入或持平，花旗維持“買入”評級，目標價18.3港元。當前股價回調，正是投機買入良機！金蝶憑藉雲服務與AI創新領跑行業，背靠穩健基本面，未來估值與股價上行空間廣闊，值得把握！

$SPDR S&P 500 ETF Trust(SPY)$ I closed $SPDR S&P 500 ETF Trust(SPY)$ ,Take a look at the latest order I posted！ I closed $SPDR S&P 500 ETF Trust(SPY)$ ,sell for now and buy again when low!I closed $SPDR S&P 500 ETF Trust(SPY)$ ,Take a look at the latest order I posted！ sell for now and buy again when low!

$Dover(DOV)$ I added to my position in Dover (DOV) following its strong Q2 2025 results, where adjusted EPS reached $2.44, beating forecasts, and revenue rose 5% to $2.05 billion. While growth was fueled more by acquisitions and currency than organic expansion, operating margins improved, and cash flow remained solid. Management’s decision to raise full-year EPS guidance to $9.35–$9.55 signals confidence despite macro uncertainties. Given Dover’s diversified portfolio, execution strength, and disciplined capital allocation, I see potential for continued resilience and shareholder value creation in the face of a mixed business environment.

$UOL(U14.SI)$ After holding for so long......

$MARA DIAGONAL 260320/251219 CALL 29.0/CALL 20.0$ Closing to take profit of $1691 + rolling it to a closer expiry, higher strike, for an extra $500.

$180 Life Sciences Corp(ATNF)$ Why I Made a Short Trade on ATNF After the Khiel News I recently made a short trade on 180 Life Sciences Corp ATNF, and it wasn't a spur-of-the-moment decision—it was a calculated move driven by the market’s heightened volatility following a significant news event. The catalyst was the announcement that Khiel had accumulated a 7.5% stake in the company. On the surface, this kind of news often excites retail investors and sparks strong buying activity. True enough, the stock experienced a sharp surge immediately after the news broke. But I saw something different: while the headlines created hype, the fundamentals and recent trading history of ATNF told me the move might be overextended. ATNF is a small-cap biote

$VanEck Vietnam ETF(VNM)$ bright outlook with young population growth